{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:21:35Z","timestamp":1787509295139,"version":"build-2736575974"},"reference-count":22,"publisher":"Japan Neurosurgical Society","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.2176\/jns-nmc.2022-0134","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T18:13:06Z","timestamp":1662142386000},"page":"275-280","source":"Crossref","is-referenced-by-count":5,"title":["A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.2176","volume":"9","author":[{"given":"Ryo","family":"MIZUTA","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"OTANI","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"FUJII","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhito","family":"UNEDA","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"ISHIDA","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"TANAKA","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"IKEGAWA","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"FUJII","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"MAEDA","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"DATE","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Gregory G, Arumugaswamy A, Leung T, et al.: Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. <i>Neuro Oncol<\/i> 15: 1068-1673, 2013","DOI":"10.1093\/neuonc\/not032"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ferreri AJ: How I treat primary CNS lymphoma. <i>Blood<\/i> 118: 510-522, 2011","DOI":"10.1182\/blood-2011-03-321349"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Rubenstein J, Ferreri AJ, Pittaluga S: Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. <i>Leukemia &amp; Lymphoma<\/i> 49: 43-51, 2008","DOI":"10.1080\/10428190802311441"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ichikawa T, Kurozumi K, Michiue H, et al.: Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. <i>Clin Neurol Neurosurg<\/i> 127: 106-111, 2014","DOI":"10.1016\/j.clineuro.2014.10.011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lee DW, Santomasso BD, Locke FL, et al.: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol Blood Marrow Transplant<\/i> 25: 625-638, 2019","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kondo E, Ikeda T, Izutsu K, et al.: High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry. <i>Biol Blood Marrow Transplant<\/i> 25: 899-905, 2019","DOI":"10.1016\/j.bbmt.2019.01.020"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Correa DD, Shi W, Abrey LE, et al.: Cognitive functions in primary CNS lymphoma after single or combined modality regimens. <i>Neuro Oncol<\/i> 14: 101-108, 2012","DOI":"10.1093\/neuonc\/nor186"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Thiel E, Korfel A, Martus P, et al.: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. <i>Lancet Oncol<\/i> 11: 1036-1047, 2010","DOI":"10.1016\/S1470-2045(10)70229-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Shah GD, Yahalom J, Correa DD, et al.: Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. <i>J Clin Oncol<\/i> 25: 4730-4735, 2007","DOI":"10.1200\/JCO.2007.12.5062"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Eshhar Z, Waks T, Gross G, Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. <i>Proc Natl Acad Sci U S A<\/i> 90: 720-724, 1993","DOI":"10.1073\/pnas.90.2.720"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Chmielewski M, Abken H: TRUCKs: the fourth generation of CARs. <i>Expert Opin Biol Ther<\/i> 15: 1145-1154, 2015","DOI":"10.1517\/14712598.2015.1046430"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Meng J, Wu X, Sun Z, et al.: Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis. <i>Front Oncol<\/i> 11: 698607, 2021","DOI":"10.3389\/fonc.2021.698607"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tu S, Zhou X, Guo Z, et al.: CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma. <i>Front Oncol<\/i> 9: 1350, 2019","DOI":"10.3389\/fonc.2019.01350"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Siddiqi T, Wang X, Blanchard MS, et al.: CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. <i>Blood Adv<\/i> 5: 4059-4063, 2021","DOI":"10.1182\/bloodadvances.2020004106"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Schuster SJ, Bishop MR, Tam CS, et al.: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. <i>N Engl J Med<\/i> 380: 45-56, 2019","DOI":"10.1056\/NEJMoa1804980"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tang K, Nastoupil LJ: Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies? <i>J Immunother Precis Oncol<\/i> 4: 150-159, 2021","DOI":"10.36401\/JIPO-21-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Abramson JS, McGree B, Noyes S, et al.: Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. <i>N Engl J Med<\/i> 377: 783-784, 2017","DOI":"10.1056\/NEJMc1704610"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Karschnia P, Blobner J, Teske N, et al.: CAR T-cells for CNS lymphoma: driving into new terrain? <i>Cancers (Basel)<\/i> 13: 2503, 2021","DOI":"10.3390\/cancers13102503"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Li T, Zhao L, Zhang Y, et al.: CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain. <i>Front Oncol<\/i> 10: 1306, 2020","DOI":"10.3389\/fonc.2020.01306"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Uneda A, Kurozumi K, Fujimura A, et al.: Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration. <i>Acta Neuropathol Commun<\/i> 9: 29, 2021","DOI":"10.1186\/s40478-021-01124-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Otani Y, Yoo JY, Lewis CT, et al.: NOTCH-induced MDSC recruitment after oHSV virotherapy in CNS cancer models modulates antitumor immunotherapy. <i>Clin Cancer Res<\/i> 28: 1460-1473, 2022","DOI":"10.1158\/1078-0432.CCR-21-2347"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Siddiqi T, Wang X, Palmer J, et al.: CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. <i>Blood<\/i> 134: 4075, 2019","DOI":"10.1182\/blood-2019-123765"}],"container-title":["NMC Case Report Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/9\/0\/9_2022-0134\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T02:05:23Z","timestamp":1662170723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/9\/0\/9_2022-0134\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":22,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2022-0134","relation":{},"ISSN":["2188-4226"],"issn-type":[{"value":"2188-4226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"article-number":"2022-0134"}}